STUDY ON ABILITY TO ENHANCE HIV-SPECIFIC IMMUNE RESPONSES

增强 HIV 特异性免疫反应能力的研究

• 批准号: 7375233
• 负责人: THOMAS C MERIGAN
• 金额: $ 1.77万
• 依托单位: STANFORD UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2005
• 资助国家: 美国
• 起止时间: 2005-12-01 至 2006-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7375233
• 关键词: STUDY; ABILITY; ENHANCE; HIV; SPECIFIC

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. A5132 is an exploratory, open-label, randomized trial to evaluate the ability of IL-2 to enhance HIV-specific immune responses and influence the rate of virologic rebound following potent antiretroviral therapy (ART) interru

该子项目是利用NIH/NCRR资助的中心赠款提供的资源的许多研究子项目之一。子项目和研究者（PI）可能从另一个NIH来源获得了主要资金，因此可以在其他CRISP条目中表示。所列机构为中心，不一定是研究者所在机构。A5132是一项探索性、开放标签、随机试验，旨在评估IL-2增强HIV特异性免疫应答的能力，并影响强效抗逆转录病毒治疗（ART）中断后病毒学反弹率。